We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gut Bacteria Are Possible Indicators of Colon Cancer Risk

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Image: Graphic representation of genomic and functional characterization of a mucosal symbiont involved in early-stage colorectal cancer (Photo courtesy of University of Washington School of Medicine)
Image: Graphic representation of genomic and functional characterization of a mucosal symbiont involved in early-stage colorectal cancer (Photo courtesy of University of Washington School of Medicine)
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum. Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and fatigue.

Colorectal cancer is a major health concern worldwide. Growing evidence for the role of the gut microbiota in the initiation of CRC has sparked interest in approaches that target these microorganisms. However, little is known about the composition and role of the microbiota associated with precancerous polyps.

A large team of medical scientists led by those at the University of Washington School of Medicine (Seattle, WA, USA) tracked 40 patients who had undergone routine colonoscopies and had biopsies taken near the polyps to identify bacteria present at relatively higher levels compared with those of patients who were polyp-free. All the patients were between the ages 50 and 75, and 60% were women. The team found distinct microbial signatures between patients with and without polyps and between polyp subtypes using sequencing and culturing techniques.

The investigators reportedly found a correlation between the common bacteria, non-enterotoxigenic Bacteroides fragilis recovered and the level of inflammatory cytokines in the mucosa adjacent to the polyp. Additional analysis revealed that B. fragilis from patients with polyps are bft-negative, activate NF-κB through Toll-like receptor 4, induce a pro-inflammatory response, and are enriched in genes associated with lipopolysaccharide (LPS) biosynthesis. They also found that the B. fragilis from patients with polyps differed in its ability to induce inflammation compared to the B. fragilis from polyp-free individuals.

William R. DePaolo, PhD, Associate Professor of Medicine and senior author of the study, said, “The whole idea is that most people look at advanced colorectal cancer and think of the microbiome, but it's hard to determine if the microbiome has changed and when it changed. What our data suggests is that, in order to survive within an environment where metabolic and inflammatory changes are occurring, a normally healthy gut and related bacteria may adapt in such a way that causes it to contribute to the inflammation rather than suppress it.”

Dr. DePaolo suggested that if a screening were available to test the microbes, before a polyp even appears, it could be a key factor to drive the rates of CRC down. The study was published on September 17, 2021, in the journal Cell Host & Microbe.

Related Links:
University of Washington School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Automatic Nucleic Acid Extractor
GeneRotex 24

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Pathology

view channel
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)

New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more